Brokerages Set Teleflex Incorporated (NYSE:TFX) PT at $141.57

Key Points

• Teleflex Incorporated has received an average recommendation of "Hold" from ten research firms, with one sell rating, eight holds, and one buy rating.
• The company reported a Q2 EPS of $3.73, surpassing expectations of $3.36, and had a revenue of $780.9 million, which also exceeded estimates.
• Teleflex declared a quarterly dividend of $0.34 per share, reflecting a 1.2% dividend yield and a payout ratio of 32%.

Teleflex Incorporated (NYSE:TFX - Get Free Report) has earned an average recommendation of "Hold" from the ten research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and one has given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $141.5714.

A number of analysts have recently weighed in on the stock. Mizuho boosted their target price on shares of Teleflex from $130.00 to $135.00 and gave the stock a "neutral" rating in a report on Friday, August 1st. Wells Fargo & Company decreased their price target on Teleflex from $137.00 to $131.00 and set an "equal weight" rating for the company in a research note on Friday, August 1st. Wall Street Zen upgraded Teleflex from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Royal Bank Of Canada boosted their price objective on shares of Teleflex from $130.00 to $135.00 and gave the company a "sector perform" rating in a research report on Friday, August 1st. Finally, Morgan Stanley reduced their price objective on Teleflex from $191.00 to $173.00 and set an "overweight" rating on the stock in a report on Monday, May 5th.

Insider Activity at Teleflex

In other news, Director Gretchen R. Haggerty purchased 500 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were acquired at an average cost of $114.75 per share, with a total value of $57,375.00. Following the completion of the acquisition, the director owned 6,305 shares of the company's stock, valued at $723,498.75. This trade represents a 8.61% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Andrew A. Krakauer acquired 1,000 shares of the firm's stock in a transaction dated Tuesday, August 5th. The shares were acquired at an average price of $115.25 per share, with a total value of $115,250.00. Following the acquisition, the director owned 7,192 shares in the company, valued at approximately $828,878. The trade was a 16.15% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 5,500 shares of company stock valued at $633,590 over the last three months. Company insiders own 1.40% of the company's stock.

Institutional Trading of Teleflex

Several large investors have recently bought and sold shares of TFX. Headlands Technologies LLC purchased a new stake in shares of Teleflex during the fourth quarter valued at $29,000. Resona Asset Management Co. Ltd. acquired a new stake in Teleflex during the 4th quarter worth about $2,471,000. Dynamic Technology Lab Private Ltd purchased a new stake in Teleflex during the 4th quarter valued at about $272,000. Russell Investments Group Ltd. increased its holdings in shares of Teleflex by 116.9% in the fourth quarter. Russell Investments Group Ltd. now owns 89,194 shares of the medical technology company's stock valued at $15,870,000 after purchasing an additional 48,064 shares during the period. Finally, Cerity Partners LLC increased its holdings in shares of Teleflex by 25.8% in the fourth quarter. Cerity Partners LLC now owns 16,822 shares of the medical technology company's stock valued at $3,266,000 after purchasing an additional 3,448 shares during the period. Hedge funds and other institutional investors own 95.62% of the company's stock.

Teleflex Stock Performance

Shares of NYSE:TFX traded up $3.08 during midday trading on Thursday, hitting $118.57. The company had a trading volume of 701,177 shares, compared to its average volume of 806,598. The company has a fifty day moving average of $118.09 and a two-hundred day moving average of $134.92. Teleflex has a 12-month low of $108.90 and a 12-month high of $249.90. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44. The company has a market cap of $5.24 billion, a price-to-earnings ratio of 27.90, a PEG ratio of 1.56 and a beta of 1.08.

Teleflex (NYSE:TFX - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.36 by $0.37. The business had revenue of $780.90 million for the quarter, compared to the consensus estimate of $771.53 million. Teleflex had a return on equity of 15.08% and a net margin of 6.31%. The business's revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the business earned $3.42 earnings per share. On average, equities research analysts expect that Teleflex will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 15th will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.36 dividend on an annualized basis and a yield of 1.1%. Teleflex's dividend payout ratio is presently 32.00%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.